Foresight Biotherapeutics, Inc.

Foresight Biotherapeutics, Inc. (Foresight) is a privately held drug development company engaged in the development of novel treatments for unmet medical needs in ophthalmology and otolaryngology. The company is focused on providing therapeutics for the treatment of diseases of the eyes and ears. The proprietary lead compound of the company, FST-100 is a novel formulation of dexamethasone that includes povidone-iodine. Foresight is being evaluated in clinical trials for the treatment of viral conjunctivitis. It is also seeking strategic partnerships and collaborations with academic, research and commercial organizations for the development and commercialization of its technologies worldwide. The company is headquartered at Andover in New York, the US.

Street: 
50 West 57th Street (15th Floor)
City: 
New York
Postcode: 
10019
Federal State : 
United States
WebSite: 
www.foresightbiotherapeutics.com
Fax: 
1-646-3653256

Company Index Score

Current Index Score Historical Index Score
  • Foresight Biotherapeutics, Inc. currently scores 50 % in the index.
  • Foresight Biotherapeutics, Inc. is currently ranked equal 15 out of a total of 35419 included in the NS Company Index. This is the top 0.042 % of all companies.
  • Foresight Biotherapeutics, Inc. is currently ranked 1 out of 4535 companies. This is in the top 0.022 % percent of Pharmaceutical companies ranked in the index.
  • User perception of the company stands at 0 % percent. This differs 50 % percent over the score attributed to the company by other scoring factors.

Latest tweets